Применение брентуксимаба ведотина для лечения ребенка, больного лимфоматоидным папулезом

Введение. Лимфоматоидный папулез — это CD30-позитивное лимфопролиферативное заболевание, протекающее с первичным поражением кожи. Одной из терапевтических опций является применение анти-CD30 моноклонального антитела брентуксимаба ведотина.

Цель: представить клиническое наблюдение эффективного лечения лимфоматоидного папулеза брентуксимабом ведотином при рефрактерности заболевания к стандартным методам терапии у 6-летнего больного.

Основные сведения. У больного К., 6 лет, после перенесенной острой респираторной вирусной инфекции отмечено появление высыпаний, расположенных преимущественно на коже конечностей, представленных единичными воспалительными папулами округлых очертаний, до 6–8 мм в диаметре, плотноватой консистенции при пальпации, с гладкой поверхностью и точечной зоной некроза белого цвета в центре отдельных элементов. Выполнена биопсия одного из элементов. По данным гистологического исследования установлен диагноз: «лимфоматоидный папулез, тип А». В связи с неэффективностью терапии топическими глюкокортикостероидными гормонами, пероральным приемом преднизолона, проведена эффективная терапия брентуксимабом ведотином.

1. Macaulay W.L. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol. 1968; 97(1): 23–30. DOI: 10.1001/archderm.97.1.23.

2. Willemze R., Meyer C.J., Van Vloten W.A., Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982; 107(2): 131– 44. DOI: 10.1111/j.1365-2133.1982.tb00331.x.

3. Martinez-Cabriales S.A., Walsh S., Sade S., Shear N.H. Lymphomatoid papulosis: an update and review. J Eur Acad Dermatol Venereol. 2020; 34(1): 59–73. DOI: 10.1111/jdv.15931.

4. Schiemann W.P., Pfeifer W.M., Levi E., et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous Tcell lymphoma. Blood. 1999; 94: 2854–61.

5. Haro R., Juarez A., Diaz J.L., et al. Regional lymphomatoid papulosis of the breast restricted to an area of prior radiotherapy. Cutis. 2016; 97: E15–9.

6. Matoula T., Nikolaou V., Marinos L., et al. Lymphomatoid papulosis type D in a fi ngolimod-treated multiple sclerosis patient. Mult Scler. 2016; 22: 1630–1.

7. Park J.H., Lee J., Lee J.H., et al. Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis. Dermatology. 2012; 225: 259–63.

8. Outlaw W., Fleischer A., Bloomfeld R. Lymphomatoid papulosis in a patient with Crohn’s disease treated with infl iximab. Infl amm Bowel Dis. 2009; 15: 965–6.

9. Leo A.M., Ermolovich T. Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol. 2009; 61: 540–1.

10. Garcia-Martinez P., Sitjas D., Llistosella E., et al. Imatinib treatment of lymphomatoid papulosis associated with myeloproliferative. Acta Derm Venereol. 2017; 97(7): 855–7. DOI: 10.2340/00015555-2669.

11. Mori M., Manuelli C., Pimpinelli N., et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood. 1999; 94(9): 3077–83.

12. Toumi A., Fazal S., Litaiem N. Lymphomatoid Papulosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

13. Uchiyama A., Motegi S., Ishikawa O. Angioinvasive lymphomatoid papulosis (type E): a fi rst Japanese case. Eur J Dermatol. 2016; 26: 507–8.

14. Nowicka D., Mertowska P., Mertowski S., et al. Etiopathogenesis, Diagnosis, and Treatment Strategies for Lymphomatoid Papulosis with Particular Emphasis on the Role of the Immune System. Cells. 2022; 11: 3697. DOI: 10.3390/cells11223697.

15. Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.

16. Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classifi cation of lymphoid neoplasms. Blood. 2016; 127(20): 2375–90. DOI: 10.1182/blood-2016-01-643569.

17. Wagner G., Rose C., Klapper W., Sachse M.M. Lymphomatoid papulosis. J Dtsch Dermatol Ges. 2020; 18(3): 199–205. DOI: 10.1111/ddg.14041.

18. Kempf W., Kerl K., Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37(1): 24–9. DOI: 10.12788/j.sder.2018.001.

19. Mani V., George R., Vijayakumar K., Nair S. Type D lymphomatoid papulosis simulating aggressive epidermotropic cytotoxic lymphoma. Indian J Pathol Microbiol. 2016; 59(1): 81–3. DOI: 10.4103/0377-4929.174823.

20. Валиев Т.Т., Ковригина А.М., Белышева Т.С. Клинические и иммуноморфологические особенности лимфоматоидного папулеза типа Е (обзор литературы и описание собственного клинического наблюдения). Клиническая онкогематология. 2020; 13(4): 389–94. DOI: 10.21320/2500-21392020-13-4-389-394.

21. Karai L.J., Kadin M.E., Hsi E.D., et al. Chromosomal rearrangements of 6p25.3 defi ne a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013; 37(8): 1173–81. DOI: 10.1097/PAS.0b013e318282d01e.

22. Pomsoong C., Suchonwanit P., Chanprapaph K., et al. Pityriasis Lichenoides Et Varioliformis Acuta and Lymphomatoid Papulosis Type F: A Case Report of Two Entities in One Patient. Clin Cosmet Investig Dermatol. 2022; 15: 1759–65. DOI: 10.2147/CCID.S379577.

23. De Souza A., Camilleri M.J., Wada D.A., et al. Clinical histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009; 61: 993–1000.

24. Bekkenk M.W., Geelen F.A., van Voorst Vader P.C., et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95: 3653–61.

25. Partarrieu-Mejías F., García-Legaz-Martínez M., Martínez-Domenech Á., et al. Methotrexate-resistant acral lymphomatoid papulosis with complete remission after psoralen-ultraviolet A therapy. Dermatol Ther. 2020; 33(4): e13782. DOI: 10.1111/dth.13782.

26. Kempf W., Pfaltz K., Vermeer M.H., et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118: 4024–35.

27. Everett M.A. Treatment of lymphomatoid papulosis with methotrexate. Br J Dermatol. 1984; 111(5): 631.

28. Vonderheid E.C., Sajjadian A., Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30- positive lymphoproliferative disorders. J Am Acad Dermatol. 1996; 34: 470–81.

29. Bruijn M.S., Horváth B., van Voorst Vader P.C., et al. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2015; 173(5): 1319–22. DOI: 10.1111/bjd.13920.

30. Fernández-de-Misa R., Hernández-Machín B., Servitje O., et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol. 2018; 43(2): 137–43. DOI: 10.1111/ced.13256.

31. Wieser I., Oh C.W., Talpur R., Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016; 74: 59–67.

32. Strathie Page S.J., Tait C.P. Mycophenolic acid in dermatology a century after its discovery. Australas J Dermatol. 2015; 56(1): 77–83. DOI: 10.1111/ajd.12259.

33. AbuHilal M., Walsh S., Shear N. Associated Hematolymphoid Malignancies in Patients With Lymphomatoid Papulosis: A Canadian Retrospective Study. J Cutan Med Surg. 2017; 21(6): 507–12. DOI: 10.1177/1203475417716366.

34. Champagne T., Walsh S. Mycophenolic acid for lymphomatoid papulosis. J Cutan Med Surg. 2013; 17(5): 332–4. DOI: 10.2310/7750.2013.12111.

35. van de Donk N.W., Dhimolea E. Brentuximab vedotin. MAbs. 2012; 4(4): 458–65. DOI: 10.4161/mabs.20230.

36. Lewis D.J., Talpur R., Huen A.O., et al. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol. 2017 Dec 1; 153(12): 1302–6. DOI: 10.1001/jamadermatol.2017.3593.

37. Горенкова Л.Г., Кравченко С.К., Белоусова И.Э. Возможности брентуксимаб ведотина в лечении рецидивирующих/рефрактерных форм кожных Т-клеточных лимфом: обзор литературы и собственные наблюдения. Вестник дерматологии и венерологии. 2019; 95(2): 42–9. DOI: 10.25208/00424609-2019-95-2-42-49.

38. Torres-Navarro I., Navarro-Mira M.Á., de Unamuno-Bustos B., Botella-Estrada R. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. J Dtsch Dermatol Ges. 2020; 18(4): 378–80. DOI: 10.1111/ddg.14064.

39. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood. 2005; 105(10): 3768–85.

40. Miquel J, Fraitag S, Hamel-Teillac D., et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol. 2014; 171(5): 1138–46. DOI: 10.1111/bjd.13061.

41. Nijsten T., Curiel-Lewandrowski C., Kadin M.E. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004; 140(3): 306–12. DOI: 10.1001/archderm.140.3.306.

42. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19): 1812–21. DOI: 10.1056/NEJMoa1002965.

43. Duvic M., Tetzlaff M.T., Gangar P., et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32): 3759–65. DOI: 10.1200/JCO.2014.60.3787.

44. Mascolo A., Scavone C., Bertini M., et al. Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. Front Pharmacol. 2020; 11: 621